New board members were selected at the 18th general shareholders meeting, and the board members appointed Kiichi Adachi as President and CEO.
Sep 23, 2019Notice
KP-100IT, recombinant human HGF for the treatment of acute spinal cord injury, was designated as an orphan drug in Japan as of September 12, 2019, with the approval of the Minister of Health, Labor and Welfare.
Jan 7, 2019Notice
Phase I/II study of recombinant human HGF, KP-100IT, for acute spinal cord injury was completed, and the clinical study report has been issued. The positive results of this study will be published later in a scientific journal and presented at academic conferences.
Jan 7, 2019Notice
Clinical data from Phase I study of recombinant human HGF, KP-100IT, for the treatment of ALS were published in Journal of Clinical Pharmacology (11 DEC 2018, DOI: 10.1002/jcph.1355). It was indicated that intrathecal administration of KP-100IT was safe and tolerable. Following the Phase I study, an investigator-initiated Phase II study is currently underway to confirm therapeutic efficacy of KP-100IT against ALS.
New board members were selected at the 17th general shareholders meeting, and the board members appointed Kiichi Adachi as President and CEO.
Jul 31, 2018Notice
Kringle Pharma successfully raised 200 million JPY in funding from THVP-1 Fund (General Partner: Tohoku University Venture Partners Co., Ltd.).
Jun 1, 2018Notice
Kringle’s recombinant human HGF is now available as a research reagent at REPROCELL, Inc. For more information, please contact REPROCELL, Inc. through their website as follows. https://www.reprocell.com/
May 11, 2018Notice
Kringle Pharma announces that the last subject has completed the follow-up period after dosing in the Phase I/II study of recombinant human HGF for acute spinal cord injury.
Feb 27, 2018Notice
A patent entitled ‘HGF preparation suitable for treatment of nervous diseases’ was granted in Japan. Patent No. JP6281992.
Jan 10, 2018Notice
Clinical data from the investigator-initiated Phase I/II of recombinant human HGF for treatment of vocal fold scar were published in Journal of Tissue Engineering and Regenerative Medicine (25 DEC 2017, DOI: 10.1002/term.2603). It was demonstrated that intracordal injection of the recombinant human HGF drug was safe, feasible, and potentially effective for vocal fold scar patients based on several evaluation methods.
Kringle Pharma’s project entitled ‘Recombinant human HGF for the treatment of acute spinal cord injury’ was accepted by Japan Agency for Medical Research and Development, AMED, as its Drug Discovery Support Promotion Project.
May 13, 2016Notice
An investigator-initiated Phase II clinical trial of recombinant human HGF started at the Tohoku and Osaka University Hospitals for the treatment of amyotrophic lateral sclerosis (ALS).
Kringle Pharma completed Phase I clinical trial of recombinant human HGF for amyotrophic lateral sclerosis (ALS). Primary objectives of the trial, the safety and pharmacokinetics of the HGF dosing, were successfully evaluated.
It is an honor to announce that Professor Kunio Matsumoto at Cancer Research Institute of Kanazawa University, the co-founder and scientific advisor of Kringle Pharma, was awarded the Prizes for Science and Technology, The Commendation for Science and Technology by the Minister of Education, Culture, Sports, Science and Technology in Japan. This was awarded to Professor Matsumoto’s prominent achievement of “Development of the application of physiologically active proteins to medical treatment.” Professor Matsumoto has devoted the strenuous efforts for many years to basic research on HGF, hepatocyte growth factor. After founding Kringle Pharma, Professor Matsumoto has been also rendering great help and assistance to the clinical development of recombinant human HGF as a therapeutic agent for intractable diseases. His outstanding contributions and achievements not only in basic science but also in applied research on physiologically active proteins have been highly acclaimed and led him to receive this most treasured prize.
In April 2012, Kringle Pharma completed Phase Ib clinical trial of recombinant human HGF in the United States. Primary objectives of the trial, the safety and pharmacokinetics of multiple intravenous dosing of HGF, were successfully evaluated.
May 1, 2012Notice
Kringle Pharma’s head office was relocated to the new address below:
207 Saito Bio-Incubator 7-7-15
Saitoasagi, Ibaraki, OSAKA
Phone: +81-72-641-8739 FAX: +81-72-641-8730
Kringle Pharma’s project entitled ‘Recombinant human HGF for the treatment of spinal cord injury’ is accepted by Japan Science and Technology Agency, JST, as its Adaptable and Seamless Technology transfer Program, A-STEP. This project has been carried out for years having its base on the collaboration with Professors Hideyuki Okano and Yoshiaki Toyama’s group at Keio University School of Medicine. JST will support Kringle to conduct a proof-of -concept clinical study of recombinant Human HGF for the treatment of acute spinal cord injury. The clinical development will be supervised by Assistant professor Masaya Nakamura in Keio University School of Medicine, as a principal investigator.
Jul 8, 2011Notice
Kringle Initiates Phase I Clinical Trial of Recombinant Human HGF for the Treatment of Incurable Neuronal Diseases.
Kringle Pharma Receives the Grand Prix of the 6th Japan Bio-Venture Award. The Japan Bio-Venture Award was founded in 2001 by Fuji Sankei Business i, one of the general business papers published by Fuji Sankei Communications Group. Since its 1st competition held in 2002, a numbers of Japanese prosperous biotech companies were honored to receive the prizes, which of those are currently playing a major role in the Japanese biotech industry.
Aug 4, 2009Notice
Kringle Pharma Finishes its Phase Ia Clinical Trial of Recombinant Human HGF for Treatment of Renal Disease.
As all of the serving board members were approved by shareholders at the 5th annual shareholders meeting (Dec. 22) to be reinstalled to their present positions, Kunio Iwatani was reappointed as President and Chief Executive Officer of Kringle Pharma at the subsequent board of directors meeting, while Kiichi Adachi was reappointed as Executive Vice President.
Nov 6, 2006Notice
Professor Toshikazu Nakamura of the Graduate School of Medicine at Osaka University and adviser to Kringle Pharma, was awarded the Medal with Purple Ribbon by the Japanese Government on November 3, 2006, for his lifetime scientific contribution to biochemistry. Professor Nakamura is a pioneer in biochemical research on HGF (hepatocyte growth factor) and is well known not only in Japan, but also throughout the world.
Apr 7, 2006Notice
Professor Toshikazu Nakamura (Advisor) and Associate Professor Kunio Matsumoto (Board Member/CSO), Graduate School of Medicine of Osaka University, received Grand Prix of the first Nature Medicine BioMedical Award for the excellent academic research titled “Discovery and therapeutic approach of NK4, an anti-cancer molecule in the 21st century”.
A meeting of the board of directors held after the 4th annual meeting of shareholders approved that Kiichi Adachi, Director of the R&D Division, be installed as Executive Vice-President on December 22, 2005, with the aim of strengthening the management. Masayoshi Matsumura resigned as director on December 22, 2005, and was installed as corporate adviser to Kringle Pharma on the same day.
Oct 27, 2005Notice
Biolex Therapeutics, a US-based company, and Kringle Pharma launched joint research on the development of low-cost mass production methods for NK4, an antitumor protein.
Apr 27, 2005Notice
Kringle Pharma allocated new shares to third parties to increase its capital by 1,325 million yen.
Apr 6, 2005Notice
Kringle Pharma concluded a joint research agreement and a license agreement with Nippon Zenyaku Kogyo to place HGF-based drugs for animal use on the market at an early date.
Feb 16, 2005Notice
Kringle Pharma concluded a joint research agreement on the development of gene medicines with DNAVEC Corporation.
Feb 14, 2005Notice
Kringle Pharma concluded a research and evaluation agreement with GaleniSearch Laboratories to develop time-release microsphere formulations based on NK4, HGF, and other related compounds.